A comprehensive review of COVID-19 virology, vaccines, variants, and therapeutics
L Forchette, W Sebastian, T Liu - Current medical science, 2021 - Springer
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of
the coronavirus disease 2019 (COVID-19), has caused more than 179 million infections and …
the coronavirus disease 2019 (COVID-19), has caused more than 179 million infections and …
[HTML][HTML] The glycosylation in SARS-CoV-2 and its receptor ACE2
Y Gong, S Qin, L Dai, Z Tian - Signal Transduction and Targeted …, 2021 - nature.com
Abstract Coronavirus disease 2019 (COVID-19), a highly infectious disease caused by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected more than …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected more than …
Estimated US infection-and vaccine-induced SARS-CoV-2 seroprevalence based on blood donations, July 2020-May 2021
Importance People who have been infected with or vaccinated against SARS-CoV-2 have
reduced risk of subsequent infection, but the proportion of people in the US with SARS-CoV …
reduced risk of subsequent infection, but the proportion of people in the US with SARS-CoV …
[HTML][HTML] Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA. 1, BA. 2, BA. 2.12. 1, BA. 4, and BA. 5
HF Tseng, BK Ackerson, KJ Bruxvoort, LS Sy… - Nature …, 2023 - nature.com
Studies have reported reduced natural SARS-CoV-2 infection-and vaccine-induced
neutralization against omicron BA. 4/BA. 5 compared with earlier omicron subvariants. This …
neutralization against omicron BA. 4/BA. 5 compared with earlier omicron subvariants. This …
[HTML][HTML] Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national …
K Maneikis, K Šablauskas, U Ringelevičiūtė… - The Lancet …, 2021 - thelancet.com
Background Haematological malignancies and their treatments are likely to affect SARS-
CoV-2 vaccine efficacy. We aimed to evaluate serological response to BNT162b2 vaccine in …
CoV-2 vaccine efficacy. We aimed to evaluate serological response to BNT162b2 vaccine in …
The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism
Vaccination-based exposure to spike protein derived from early SARS-CoV-2 sequences is
the key public health strategy against COVID-19. Successive waves of SARS-CoV-2 …
the key public health strategy against COVID-19. Successive waves of SARS-CoV-2 …
SARS-CoV-2 S2–targeted vaccination elicits broadly neutralizing antibodies
Several variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have
emerged during the current coronavirus disease 2019 (COVID-19) pandemic. Although …
emerged during the current coronavirus disease 2019 (COVID-19) pandemic. Although …
[HTML][HTML] The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study
Background Among the most consequential unknowns of the devastating COVID-19
pandemic are the durability of immunity and time to likely reinfection. There are limited direct …
pandemic are the durability of immunity and time to likely reinfection. There are limited direct …
[HTML][HTML] Immunogenicity and reactogenicity of vaccine boosters after Ad26. COV2. S priming
RSG Sablerolles, WJR Rietdijk… - … England Journal of …, 2022 - Mass Medical Soc
Abstract Background The Ad26. COV2. S vaccine, which was approved as a single-shot
immunization regimen, has been shown to be effective against severe coronavirus disease …
immunization regimen, has been shown to be effective against severe coronavirus disease …
Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine
Humans commonly have low level antibodies to poly (ethylene) glycol (PEG) due to
environmental exposure. Lipid nanoparticle (LNP) mRNA vaccines for SARS-CoV-2 contain …
environmental exposure. Lipid nanoparticle (LNP) mRNA vaccines for SARS-CoV-2 contain …